The efficacy of the use of Cellular Matrix-BCT-HA (combination of autologous platelet-rich plasma and non-cross-linked hyaluronic acid) compared to local estrogen therapy (Blissel, estriol 50 micrograms/g vaginal gel) in women with genitourinary syndrome of menopause. A randomized controlled trial, with a second blind observer.

genitourinary syndrome of menopause

The primary efficacy criteria is the percentage of patients with improved symptomatology. Improvement is defined as having a higher score than the baseline in the Vaginal Health Index (VHIS) evaluated at 6 months after treatment.

Healing percentage defined as percentage of patients scoring ≥ 15 in the VHIS at 6 months after treatment., Evolution of Vaginal Health Index at 3-months and 6-months follow-up, Evolution of Vulvar Health Index at 3- and 6-months follow-up, Evolution of vaginal pH at 3- and 6-months follow-up, Evolution of Vaginal maturation index (vaginal cytology) at 3- and 6-months follow-up, Evolution of intensity of VVA symptoms (vaginal burning, vaginal itching, vaginal dryness, dyspareunia, and dysuria) will be measured using a 5-cm visual analog scale (VAS) at 3- and 6-months follow-up, Evolution of Female Sexual Distress (FSD) score at 3- and 6-months follow-up, Photographic monitoring at 3- and 6-months follow-up

No related papers found yet.

Papers published before 2008-02-04 may not appear yet. Historical indexing is in progress.

Spain